Predicting recurrence in early-stage hormone-sensitive breast cancer
Part of Cancer, Skin clinical trials.
This study looks at what makes early breast cancer (that hasn't spread beyond the breast or nearby lymph nodes) more likely to come back after treatment. It uses your medical records to build a better way to predict recurrence, which could help personalize follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of breast cancer called HR+/HER2-
- You had surgery for your breast cancer and then took hormone therapy (or had hormone therapy before surgery)
- Your cancer has not spread to distant parts of the body (it is not Stage IV)
- You are a woman
- Your medical records are complete, including follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world patterns and the risk of cancer returning after surgery in people with early-stage breast cancer that is hormone receptor positive and HER2 negative. By reviewing medical records, researchers hope to learn more about what affects recurrence to improve future care.
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
This trial looks at how certain proteins (ER, PR, and HER2/neu) on breast cancer cells change when the cancer comes back in the same spot. Knowing this could help doctors choose the best treatment for your recurrence.
This study tracks tiny traces of cancer DNA in the blood over time to see if it can find early signs of breast cancer coming back. It looks at different types of breast cancer and at different points in a patient's treatment journey.
This trial studies early, hormone receptor–positive, HER2-negative breast cancer and looks at a group with “high clinical risk” but “low genetic (tumor) risk.” It may help researchers understand which patients may benefit most from treatment decisions guided by genetic tumor testing.
Hear when a new Breast Cancer, HR+/HER2- Early-Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.